Nathalie Adda - 01 Dec 2021 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Sr. VP & Chief Medical Officer
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
01 Dec 2021
Transactions value $
-$629,656
Form type
4
Filing time
03 Dec 2021, 18:02:59
Previous filing
23 Nov 2021
Next filing
13 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Tax liability -$73.8K -842 -2.5% $87.68* 32.9K 01 Dec 2021 Direct F1
transaction ENTA Common Stock Options Exercise $380K +8.75K +26.59% $43.46 41.7K 01 Dec 2021 Direct
transaction ENTA Common Stock Options Exercise $232K +4.77K +11.46% $48.52 46.4K 01 Dec 2021 Direct
transaction ENTA Common Stock Sale -$135K -1.59K -3.42% $84.81* 44.8K 01 Dec 2021 Direct F2, F3
transaction ENTA Common Stock Sale -$490K -5.74K -12.79% $85.49* 39.1K 01 Dec 2021 Direct F2, F4
transaction ENTA Common Stock Sale -$233K -2.7K -6.91% $86.45* 36.4K 01 Dec 2021 Direct F2, F5
transaction ENTA Common Stock Sale -$131K -1.5K -4.12% $87.60* 34.9K 01 Dec 2021 Direct F2, F6
transaction ENTA Common Stock Sale -$79.5K -900 -2.58% $88.31* 34K 01 Dec 2021 Direct F2, F7
transaction ENTA Common Stock Sale -$80.3K -899 -2.64% $89.33* 33.1K 01 Dec 2021 Direct F2, F8
transaction ENTA Common Stock Sale -$18.1K -201 -0.61% $90.17* 32.9K 01 Dec 2021 Direct F2, F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -8.75K -15.98% $0.00 46K 01 Dec 2021 Common Stock 8.75K $43.46 Direct F10
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -4.77K -34.21% $0.00 9.18K 01 Dec 2021 Common Stock 4.77K $48.52 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.43 to $84.98, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $85.04 to $85.98, inclusive.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $86.03 to $86.91, inclusive.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $87.23 to $87.92, inclusive.
F7 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $88.01 to $88.90, inclusive.
F8 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $89.02 to $89.88, inclusive.
F9 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.25, inclusive.
F10 100% of the shares subject to the option are fully vested and exercisable.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 9 above.